In addition, the expression level of MMS22L was higher in patients with higher HCC grades, suggesting that MMS22L participated in the clinical process and related to the malignancy of patients with HCC (Figures 7E–H). The gene discussed is MMS22L; the disease is hepatocellular carcinoma.